Skip to content

Assessment of the Acute Effect of IP

A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Acute Effect of IP on hGH Levels in Aging Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03658187
Enrollment
32
Registered
2018-09-05
Start date
2018-07-19
Completion date
2019-01-25
Last updated
2019-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deficiency Growth Hormone

Brief summary

It is a nutraceutical system, consisting of oral tablet and an oral spray called Alpha GPC, which helps your body naturally restore the HGH levels.

Interventions

DIETARY_SUPPLEMENTPlacebo

Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.

DIETARY_SUPPLEMENTIP

Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.

Sponsors

Vedic Lifesciences Pvt. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and females having age between 40-60 years (both inclusive) * BMI ≥25 and ≤29.9 kg/m2 * FBS ≤ 120 mg/dl * Serum hGH levels ≤0.94 ng/ml in females and ≤0.12 in males * Thyroid Stimulating Hormone ≥ 0.35 and ≤ 5.55 mIU/ml

Exclusion criteria

* History of thyroid disorder (Hyper/Hypo). * Smokers having at least 1 cigarette per day. * Known hypersensitivity or allergy to one or more of the ingredients of the IP * Participant suffering from primary or secondary insomnia with/without active treatment. * Alcoholics as defined by consumption of more than 2 standard alcoholic drinks (more than 30 ml/ day) for past 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Change in the plasma human growth hormone (hGH) levels in aging individualsPre-dose: 0 hours and Post dose: 30, 60, 90,120 minsChange in serum hGH levels from baseline

Secondary

MeasureTime frameDescription
Change on Visual Analogue Score for FatigueFrom Day 0 to Day 1Change in Visual Analogue Scale score in IP and placebo.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026